Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Companies

In the dynamic world of pharmaceuticals, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Perrigo Company plc and Viking Therapeutics, Inc. have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses.

Perrigo, a well-established player, has consistently allocated a significant portion of its budget to SG&A, with a notable increase of approximately 89% from 2014 to 2023. This trend reflects its commitment to maintaining a robust market presence and operational efficiency. In contrast, Viking Therapeutics, a smaller and more agile entity, has shown a remarkable 2,873% surge in SG&A spending over the same period, indicating aggressive expansion and investment in growth opportunities.

These divergent strategies highlight the varied paths companies take to achieve success in the competitive pharmaceutical landscape, offering a fascinating glimpse into their operational philosophies.